Up­dat­ed: J&J ax­es four-year dis­cov­ery al­liance with Mor­phic

J&J and Har­vard spin­out Mor­phic Ther­a­peu­tic are part­ing ways af­ter four years of work­ing to­geth­er on find­ing small mol­e­cule drugs that can act on new in­te­grin tar­gets.

Mor­phic qui­et­ly dis­closed on Fri­day that it re­ceived a ter­mi­na­tion no­tice from J&J’s Janssen a week ago. Ab­b­Vie broke off a sim­i­lar deal with Mor­phic back in June. In its fil­ing, the biotech did not spec­i­fy why Janssen walked away, not­ing on­ly that the phar­ma part­ner ex­er­cised its right to end the R&D col­lab­o­ra­tion “for con­ve­nience.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER